286 related articles for article (PubMed ID: 24067534)
1. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
Milch C; Wyant T; Xu J; Parikh A; Kent W; Fox I; Berger J
J Neuroimmunol; 2013 Nov; 264(1-2):123-6. PubMed ID: 24067534
[TBL] [Abstract][Full Text] [Related]
2. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
Garnock-Jones KP
BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
[TBL] [Abstract][Full Text] [Related]
4. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
[TBL] [Abstract][Full Text] [Related]
5. Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.
Boden EK; Shows DM; Chiorean MV; Lord JD
Dig Dis Sci; 2018 Sep; 63(9):2419-2429. PubMed ID: 29372476
[TBL] [Abstract][Full Text] [Related]
6. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.
D'Haens G; Vermeire S; Vogelsang H; Allez M; Desreumaux P; Van Gossum A; Sandborn WJ; Baumgart DC; Ransohoff RM; Comer GM; Ahmad A; Cataldi F; Cheng J; Clare R; Gorelick KJ; Kaminski A; Pradhan V; Rivers S; Sikpi MO; Zhang Y; Hassan-Zahraee M; Reinisch W; Stuve O
J Crohns Colitis; 2018 Jan; 12(2):188-196. PubMed ID: 28961770
[TBL] [Abstract][Full Text] [Related]
7. Blockade of αEβ7 integrin suppresses accumulation of CD8
Zundler S; Schillinger D; Fischer A; Atreya R; López-Posadas R; Watson A; Neufert C; Atreya I; Neurath MF
Gut; 2017 Nov; 66(11):1936-1948. PubMed ID: 27543429
[TBL] [Abstract][Full Text] [Related]
8. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
Wyant T; Fedyk E; Abhyankar B
J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.
Tilg H; Kaser A
Curr Opin Investig Drugs; 2010 Nov; 11(11):1295-304. PubMed ID: 21157649
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab for the treatment of inflammatory bowel disease.
Haddley K
Drugs Today (Barc); 2014 Apr; 50(4):309-19. PubMed ID: 24918648
[TBL] [Abstract][Full Text] [Related]
11. What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?
Card T; Xu J; Liang H; Bhayat F
Inflamm Bowel Dis; 2018 Apr; 24(5):953-959. PubMed ID: 29668955
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
Poulakos M; Machin JD; Pauly J; Grace Y
J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
[TBL] [Abstract][Full Text] [Related]
13. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
Wittner M; Schlicker V; Libera J; Bockmann JH; Horvatits T; Seiz O; Kummer S; Manthey CF; Hüfner A; Kantowski M; Rösch T; Degen O; Huber S; Eberhard JM; Schulze Zur Wiesch J
PLoS One; 2019; 14(7):e0220008. PubMed ID: 31356607
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo.
Fischer A; Zundler S; Atreya R; Rath T; Voskens C; Hirschmann S; López-Posadas R; Watson A; Becker C; Schuler G; Neufert C; Atreya I; Neurath MF
Gut; 2016 Oct; 65(10):1642-64. PubMed ID: 26209553
[TBL] [Abstract][Full Text] [Related]
16. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
Schleier L; Wiendl M; Heidbreder K; Binder MT; Atreya R; Rath T; Becker E; Schulz-Kuhnt A; Stahl A; Schulze LL; Ullrich K; Merz SF; Bornemann L; Gunzer M; Watson AJM; Neufert C; Atreya I; Neurath MF; Zundler S
Gut; 2020 Feb; 69(2):252-263. PubMed ID: 31092589
[TBL] [Abstract][Full Text] [Related]
17. Vedolizumab for the treatment of ulcerative colitis.
Rietdijk ST; D'Haens GR
Expert Rev Clin Pharmacol; 2014 Jul; 7(4):423-30. PubMed ID: 24802046
[TBL] [Abstract][Full Text] [Related]
18. The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis.
Besendorf L; Müller TM; Geppert CI; Schneider I; Mühl L; Atreya I; Vitali F; Atreya R; Neurath MF; Zundler S
Therap Adv Gastroenterol; 2022; 15():17562848221098899. PubMed ID: 35784193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
